Cargando…

Alpha-1 antitrypsin Pi∗Z allele is an independent risk factor for liver transplantation and death in patients with advanced chronic liver disease

BACKGROUND & AIMS: Alpha-1 antitrypsin (AAT) deficiency causes/predisposes individuals to advanced chronic liver disease (ACLD). However, the role of the SERPINA1 Pi∗Z allele in patients who have already progressed to ACLD is unclear. Thus, we aimed to evaluate the impact of the Pi∗Z allele on t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Balcar, Lorenz, Scheiner, Bernhard, Urheu, Markus, Weinberger, Patrick, Paternostro, Rafael, Simbrunner, Benedikt, Hartl, Lukas, Jachs, Mathias, Bauer, David, Semmler, Georg, Willheim, Claudia, Pinter, Matthias, Ferenci, Peter, Trauner, Michael, Reiberger, Thomas, Stättermayer, Albert Friedrich, Mandorfer, Mattias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513767/ https://www.ncbi.nlm.nih.gov/pubmed/36176936 http://dx.doi.org/10.1016/j.jhepr.2022.100562

Ejemplares similares

Impact of ammonia levels on outcome in clinically stable outpatients with advanced chronic liver disease
por: Balcar, Lorenz, et al.
Publicado: (2023)

Patterns of acute decompensation in hospitalized patients with cirrhosis and course of acute‐on‐chronic liver failure
por: Balcar, Lorenz, et al.
Publicado: (2021)

Impact of farnesoid X receptor single nucleotide polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension
por: Semmler, Georg, et al.
Publicado: (2019)

COVID‐19‐Related Downscaling of In‐Hospital Liver Care Decreased Patient Satisfaction and Increased Liver‐Related Mortality
por: Hartl, Lukas, et al.
Publicado: (2021)

Safety of direct oral anticoagulants in patients with advanced liver disease
por: Semmler, Georg, et al.
Publicado: (2021)

An impaired pituitary–adrenal signalling axis in stable cirrhosis is linked to worse prognosis
por: Hartl, Lukas, et al.
Publicado: (2023)

Non‐invasive detection of portal hypertension by enhanced liver fibrosis score in patients with different aetiologies of advanced chronic liver disease
por: Simbrunner, Benedikt, et al.
Publicado: (2020)

Influence of Genetic Variants on Disease Regression and Outcomes in HCV-Related Advanced Chronic Liver Disease after SVR
por: Semmler, Georg, et al.
Publicado: (2021)

Prevalence of and risk factors for anaemia in patients with advanced chronic liver disease
por: Scheiner, Bernhard, et al.
Publicado: (2019)

Long-Term Outcome of HBV-Infected Patients with Clinically Significant Portal Hypertension Achieving Viral Suppression
por: Jachs, Mathias, et al.
Publicado: (2022)

Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension
por: Semmler, Georg, et al.
Publicado: (2019)

Gut-liver axis signaling in portal hypertension
por: Simbrunner, Benedikt, et al.
Publicado: (2019)

The systemic and hepatic alternative renin–angiotensin system is activated in liver cirrhosis, linked to endothelial dysfunction and inflammation
por: Hartl, Lukas, et al.
Publicado: (2023)

Acute hemodynamic response to propranolol predicts bleeding and nonbleeding decompensation in patients with cirrhosis
por: Hofer, Benedikt S., et al.
Publicado: (2022)

Von Willebrand factor processing in patients with advanced chronic liver disease and its relation to portal hypertension and clinical outcome
por: Simbrunner, Benedikt, et al.
Publicado: (2023)

Renin/angiotensin system-coagulation-inflammation axis abnormalities: a possible explanation for susceptibility to severe COVID-19 in cirrhosis
por: Hartl, Lukas, et al.
Publicado: (2022)

Imaging features facilitate diagnosis of porto-sinusoidal vascular disorder
por: Lampichler, Katharina, et al.
Publicado: (2022)

Impact of HSD17B13 rs72613567 genotype on hepatic decompensation and mortality in patients with portal hypertension
por: Scheiner, Bernhard, et al.
Publicado: (2019)

Age‐adjusted mortality and predictive value of liver chemistries in a Viennese cohort of COVID‐19 patients
por: Hartl, Lukas, et al.
Publicado: (2022)

Vitamin A levels reflect disease severity and portal hypertension in patients with cirrhosis
por: Simbrunner, Benedikt, et al.
Publicado: (2020)

Cirrhosis-Associated RAS-Inflammation-Coagulation Axis Anomalies: Parallels to Severe COVID-19
por: Hartl, Lukas, et al.
Publicado: (2021)

Antibiotic Therapy is Associated with Worse Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib
por: Pomej, Katharina, et al.
Publicado: (2021)

Systemic inflammation is linked to liver fibrogenesis in patients with advanced chronic liver disease
por: Simbrunner, Benedikt, et al.
Publicado: (2022)

COVID-19 pandemic: Impact on the management of patients with hepatocellular carcinoma at a tertiary care hospital
por: Pomej, Katharina, et al.
Publicado: (2021)

Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID‐19 in patients with chronic liver disease
por: Hartl, Lukas, et al.
Publicado: (2022)

Incidence, phenotype and prognostic relevance of COVID-19-related liver injury across different age strata
por: Hartl, Lukas, et al.
Publicado: (2022)

The impact of hepatic steatosis on portal hypertension
por: Semmler, Georg, et al.
Publicado: (2019)

Early changes in immunoglobulin G levels during immune checkpoint inhibitor treatment are associated with survival in hepatocellular carcinoma patients
por: Balcar, Lorenz, et al.
Publicado: (2023)

Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver Disease
por: Semmler, Georg, et al.
Publicado: (2021)

Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease
por: Scheiner, Bernhard, et al.
Publicado: (2018)

Eligibility for antiviral therapy and treatment uptake in chronic hepatitis B patients referred to a European tertiary care center
por: Jachs, Mathias, et al.
Publicado: (2023)

Long-term follow-up of patients discontinuing bulevirtide treatment upon long-term HDV-RNA suppression
por: Jachs, Mathias, et al.
Publicado: (2023)

Distinct prognostic value of different portal hypertension-associated features in patients with primary biliary cholangitis
por: Burghart, Lukas, et al.
Publicado: (2021)

Recent advances in the understanding and management of hepatorenal syndrome
por: Simbrunner, Benedikt, et al.
Publicado: (2021)

The differential activation of cardiovascular hormones across distinct stages of portal hypertension predicts clinical outcomes
por: Hartl, Lukas, et al.
Publicado: (2021)

The impact of COVID-19 on liver transplantation programs in Austria
por: Hartl, Lukas, et al.
Publicado: (2022)

Vascular Complications in Patients with Hepatocellular Carcinoma Treated with Sorafenib
por: Pomej, Katharina, et al.
Publicado: (2020)

The Impact of PNPLA3 rs738409 SNP on Liver Fibrosis Progression, Portal Hypertension and Hepatic Steatosis in HIV/HCV Coinfection
por: Scheiner, Bernhard, et al.
Publicado: (2015)

The ‘Viennese epidemic’ of acute HCV in the era of direct‐acting antivirals
por: Chromy, David, et al.
Publicado: (2022)

Heterozygosity for the alpha‐1‐antitrypsin Z allele in cirrhosis is associated with more advanced disease
por: Schaefer, Benedikt, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_69nhee9comp27ms24jt5khmcco